Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
Erlotinib and Temsirolimus for Solid Tumors
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 46
- Registration Number
- NCT00770263
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 81
- Registration Number
- NCT00769483
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 188
- Registration Number
- NCT00769067
- Locations
- 🇵🇱
Medex spolka cywilna, Chrzanow, Poland
🇪🇸Hospital de Cruces, Barakaldo, Vizcaya, Spain
🇵🇱"Vesalius" Sp. z o.o., Krakow, Poland
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
- Conditions
- Interventions
- First Posted Date
- 2008-10-06
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00766636
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00761345
- Locations
- 🇺🇸
Karmanos Cancer Institue, Detroit, Michigan, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Reading Medical Center, West Reading, Pennsylvania, United States
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00759928
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
- First Posted Date
- 2008-09-10
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT00750698
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Sharp Clinical Oncology Research, San Diego, California, United States
Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
- First Posted Date
- 2008-09-10
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Geisinger Clinic
- Target Recruit Count
- 4
- Registration Number
- NCT00750555
- Locations
- 🇺🇸
Geisinger Health System, Danville, Pennsylvania, United States
Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 13
- Registration Number
- NCT00749567
- Locations
- 🇬🇷
University Hospital of Heraklion, Heraklion, Crete, Greece
🇬🇷Air Forces Military Hospital, Dep of Medical Oncology, Athens, Greece
🇬🇷University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 141
- Registration Number
- NCT00743938
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Hema/Oncology Assoc. Of Nepa, Dunmore, Pennsylvania, United States
🇺🇸Cancer Center Of The Carolinas, Greenville, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.